PGNX - Progenics Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.4100
-0.2400 (-5.16%)
As of 1:02PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close4.6500
Open4.6000
Bid4.4100 x 1200
Ask4.4200 x 1000
Day's Range4.3800 - 4.6300
52 Week Range3.6200 - 9.4200
Volume390,068
Avg. Volume1,196,972
Market Cap372.832M
Beta (3Y Monthly)2.13
PE Ratio (TTM)N/A
EPS (TTM)-0.9030
Earnings DateOct 31, 2018 - Nov 5, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.92
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents13 hours ago

    Edited Transcript of PGNX earnings conference call or presentation 9-May-19 12:30pm GMT

    Q1 2019 Progenics Pharmaceuticals Inc Earnings Call

  • GlobeNewswire6 days ago

    Progenics Pharmaceuticals and ROTOP Pharmaka GmbH Announce European Collaboration for Prostate Cancer Imaging Agent 1404

    NEW YORK & DRESDEN, Germany, May 14, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, and ROTOP Pharmaka GmbH, a leading radiopharmaceuticals company focused on diagnostics and therapeutics, today announced an exclusive agreement under which ROTOP agreed to develop and commercialize 1404 in Europe. 1404 is Progenics’ prostate specific membrane antigen (PSMA)-targeted small molecule SPECT/CT imaging agent labeled with technetium-99m that is designed to visualize prostate cancer.

  • PR Newswire7 days ago

    Velan Implores for Improved Transparency and Real Change at Progenics Pharmaceuticals Following Q1 2019 Earnings Call

    ALPHARETTA, Ga., May 13, 2019 /PRNewswire/ -- Velan Capital, L.P. (together with its affiliates, "Velan" or "we"), one of the largest stockholders of Progenics Pharmaceuticals, Inc. ("Progenics", "you" or the "Company")(PGNX), today publicly called on the Company's management team and Board of Directors (the "Board") to increase the level of disclosure and transparency to stockholders given its apparent failure to do so in the Company's first quarter 2019 earnings call held on May 9, 2019.

  • Progenics Pharmaceuticals (PGNX) Q1 2019 Earnings Call Transcript
    Motley Fool10 days ago

    Progenics Pharmaceuticals (PGNX) Q1 2019 Earnings Call Transcript

    PGNX earnings call for the period ending March 31, 2019.

  • Progenics (PGNX) Reports Q1 Loss, Tops Revenue Estimates
    Zacks11 days ago

    Progenics (PGNX) Reports Q1 Loss, Tops Revenue Estimates

    Progenics (PGNX) delivered earnings and revenue surprises of 8.33% and 15.39%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press11 days ago

    Progenics: 1Q Earnings Snapshot

    The New York-based company said it had a loss of 22 cents per share. The biopharmaceutical company posted revenue of $4.3 million in the period. Progenics shares have increased 24% since the beginning ...

  • GlobeNewswire11 days ago

    Progenics Pharmaceuticals Announces First Quarter 2019 Financial Results and Business Update

    Progenics Pharmaceuticals, Inc. (PGNX) today announced financial results for the first quarter 2019 and provided a business update. Mr. Baker continued, “We have also made excellent progress across our PSMA-targeted prostate cancer pipeline designed to find, fight and follow cancer.

  • PR Newswire12 days ago

    Velan Calls for Increased Transparency at Progenics Pharmaceuticals During Q1 Earnings Call

    Filed Preliminary Proxy Materials Seeking Stockholder Support Against the Election of Peter J. Crowley and Michael D. Kishbauch at the Company's 2019 Annual Meeting to Send a Clear Message that Meaningful ...

  • GlobeNewswire13 days ago

    Progenics Pharmaceuticals Comments on Velan Capital’s Preliminary Proxy Statement

    The Progenics Board of Directors is deeply committed to enhancing value for all shareholders and overseeing the Company’s strategy. The Board recognizes the importance of having the right mix of skills, expertise and experience to effectively oversee the Company and regularly reviews the Board’s composition and its refreshment to ensure alignment with the interests of shareholders.

  • GlobeNewswire14 days ago

    Progenics Pharmaceuticals Issues Statement Regarding Velan Capital

    Progenics Board Deeply Committed to Enhancing Value for all Shareholders Repeated Efforts to Engage Meaningfully with Velan Rebuffed No Shareholder Action Required at this.

  • GlobeNewswire14 days ago

    Data Presented at the 2019 American Urological Association (AUA) Annual Meeting Showcases Potential for Progenics’ PyL Imaging Agent

    Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that data highlighting the potential of its PyL imaging agent was featured in two oral presentations at the 2019 American Urological Association (AUA) Annual Meeting in Chicago, Illinois.

  • PR Newswire14 days ago

    Velan Delivers Letter to the Board of Progenics Pharmaceuticals

    ALPHARETTA, Ga., May 6, 2019 /PRNewswire/ -- Velan Capital, L.P. (together with its affiliates, "Velan"), one of the largest stockholders of Progenics Pharmaceuticals, Inc. (the "Company")(PGNX), today announced that it has delivered a letter to the Board of Directors (the "Board") of the Company expressing its concerns with the Company's persistent underperformance and poor corporate governance practices and stating its intent to hold certain members of the Board accountable at the Company's 2019 Annual Meeting of Stockholders.

  • GlobeNewswire18 days ago

    Progenics Pharmaceuticals Sets First Quarter 2019 Financial Results and Business Update Call for May 9

    Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that it will host a conference call and webcast to review first quarter ended March 31, 2019 financial results on Thursday, May 9, 2019, at 8:30 a.m. ET. Forward looking statements generally will be accompanied by words such as "anticipate," "believe," "plan," "could," "should," "estimate," "expect," "forecast," "outlook," "guidance," "intend," "may," "might," "will," "possible," "potential," "predict," "project," or other similar words, phrases or expressions.

  • Earnings Preview: Progenics (PGNX) Q1 Earnings Expected to Decline
    Zacks19 days ago

    Earnings Preview: Progenics (PGNX) Q1 Earnings Expected to Decline

    Progenics (PGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire26 days ago

    Results from Clinical Trial Show Progenics’ PyL (18F-DCFPyL) PSMA PET/CT Imaging Agent Changes Management Plans for More Than 87% of Patients

    Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that an analysis of an ongoing investigator-initiated study of PyLTM (18F-DCFPyL) in 130 men with biochemical recurrence of prostate cancer has been published in The Journal of Nuclear Medicine. PyL is Progenics’ PSMA-targeted small molecule PET/CT imaging agent designed to visualize prostate cancer. The publication is an analysis of an ongoing investigator-initiated prospective study of PyL, which is being conducted by the University of British Columbia and British Columbia Cancer Agency.

  • Barrons.comlast month

    Investor Altiva Wants to Repopulate Progenics’ Board

    In a series of filings concerning the Pennsylvania-based bank over the past week, activists CT Opportunity Management and Driver Management disclosed that they had submitted proposed terms on March 23. The activist investors, filing together on April 4, reported that DNB Financial had declined to accept the term sheet.

  • TheStreet.comlast month

    These 3 Biotech Stocks Are Moving Closer to Profitability

    First quarter earnings season kicks off today as we get results from the major banks. While profits are projected to be slightly down from the same period a year ago from companies within the S&P 500, the market seems to be taking this in stride for now.

  • How Many Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Shares Did Insiders Buy, In The Last Year?
    Simply Wall St.last month

    How Many Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Shares Did Insiders Buy, In The Last Year?

    We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that there are more than a few examples of insiders dumping stock prior to a period of weak performance. So before you...

  • GlobeNewswire2 months ago

    Progenics Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference

    Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that Mark R. Baker, Chief Executive Officer, will present at the 18th Annual Needham Healthcare Conference in New York City on Wednesday, April 10, 2019 at 10:40 a.m. Eastern Time. Forward looking statements generally will be accompanied by words such as "anticipate," "believe," "plan," "could," "should," "estimate," "expect," "forecast," "outlook," "guidance," "intend," "may," "might," "will," "possible," "potential," "predict," "project," or other similar words, phrases or expressions.

  • GlobeNewswire2 months ago

    Progenics Pharmaceuticals Announces Presentations at the 2019 American Urological Association (AUA) Annual Meeting

    NEW YORK, April 03, 2019 -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find,.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of PGNX earnings conference call or presentation 14-Mar-19 12:30pm GMT

    Q4 2018 Progenics Pharmaceuticals Inc Earnings Call

  • TheStreet.com2 months ago

    My Post-Earnings Assessment of 2 Biotech Stocks

    Fourth quarter earnings season has been largely over for large cap names for some time now. However, we still are seeing a trickle of Q4 results come in for some smaller biotech and biopharma names. I thought today we would take a look at a couple of companies we have covered on these pages before and do a post-earnings assessment on them.

  • Progenics (PGNX) Reports Q4 Loss, Misses Revenue Estimates
    Zacks2 months ago

    Progenics (PGNX) Reports Q4 Loss, Misses Revenue Estimates

    Progenics (PGNX) delivered earnings and revenue surprises of -112.50% and -70.54%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Progenics: 4Q Earnings Snapshot

    On a per-share basis, the New York-based company said it had a loss of 17 cents. The biopharmaceutical company posted revenue of $3.2 million in the period. For the year, the company reported that its ...

  • Benzinga2 months ago

    The Daily Biotech Pulse: Arsanis Completes X4 Merger, EC Nod For Roche, Axovant Offering

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 13) Abbott Laboratories (NYSE: ABT ) Akari Therapeutics ...